GRIFMAN et al., 1997 - Google Patents
Differentiation intensifies the susceptibility of pheochromocytoma cells to antisense oligodeoxynucleotide-dependent suppression of acetylcholinesterase activityGRIFMAN et al., 1997
View PDF- Document ID
- 8539322337703593641
- Author
- GRIFMAN M
- SOREQ H
- Publication year
- Publication venue
- Antisense and Nucleic Acid Drug Development
External Links
Snippet
To investigate the effect of neuronal differentiation on the capacity of antisense oligonucleotides (AS-ODNs) to suppress the production of acetylcholinesterase (AChE) in rat pheochromocytoma cells, we tested seven 3‵-phosphorothioated AS-ODNs targeted to …
- 108010022752 Acetylcholinesterase 0 title abstract description 61
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Le Grand et al. | Neural stem cells in Parkinson’s disease: a role for neurogenesis defects in onset and progression | |
| US11926829B2 (en) | Allele-specific silencing therapy for dynamin 2-related diseases | |
| Rincón Castro et al. | Novel targets for valproic acid: up‐regulation of melatonin receptors and neurotrophic factors in C6 glioma cells | |
| Brenner et al. | The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis | |
| van deVondervoort et al. | Long non-coding RNAs in neurodevelopmental disorders | |
| Dreyer | Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions | |
| Zhang et al. | miR‐141‐3p inhibits vascular smooth muscle cell proliferation and migration via regulating Keap1/Nrf2/HO‐1 pathway | |
| GRIFMAN et al. | Differentiation intensifies the susceptibility of pheochromocytoma cells to antisense oligodeoxynucleotide-dependent suppression of acetylcholinesterase activity | |
| Dang et al. | CHRFAM7A: a human-specific α7-nicotinic acetylcholine receptor gene shows differential responsiveness of human intestinal epithelial cells to LPS | |
| WO2007135426A2 (en) | Treatment of neurodegeneratives diseases | |
| Lev-Lehman et al. | Synaptogenesis and myopathy under acetylcholinesterase overexpression | |
| Wang et al. | ssc-miR-7134-3p regulates fat accumulation in castrated male pigs by targeting MARK4 gene | |
| Huang et al. | miR-873a-5p targets A20 to facilitate morphine tolerance in mice | |
| Meares et al. | MicroRNA‐31 is required for astrocyte specification | |
| Shi et al. | miR-124 alleviates ischemic stroke-induced neuronal death by targeting DAPK1 in mice | |
| JP2010512786A (en) | Inhibitory polynucleotide compositions and methods for treating cancer | |
| Tawarayama et al. | Cyclin-dependent kinase inhibitor 2b mediates excitotoxicity-induced death of retinal ganglion cells | |
| Mao et al. | Dysregulation of miR-146a: a causative factor in epilepsy pathogenesis, diagnosis, and prognosis | |
| US6121046A (en) | Synthetic antisense oligodeoxynucleotides targeted to human ache | |
| Liu et al. | Atsttrin reduces lipopolysaccharide-induced neuroinflammation by inhibiting the nuclear factor kappa B signaling pathway | |
| US9347085B2 (en) | Methods and compositions for reducing amyloid beta levels | |
| Chung et al. | Lmx1a regulates dopamine transporter gene expression during ES cell differentiation and mouse embryonic development | |
| Castillo et al. | The influence of the prolactin/vasoinhibin axis on post‐stroke lesion volume, astrogliosis, and survival | |
| Huang et al. | Targeting novel human transient receptor potential ankyrin 1 splice variation with splice-switching antisense oligonucleotides | |
| WO1998026062A9 (en) | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |